Navigation Links
Molecular atlas provides new tool for understanding estrogen-fueled breast cancer

Lurking in unexplored regions of the human genome are thousands of previously unknown on/off switches that may influence how the growth of breast cancer is driven by estrogen, new research by Dana-Farber Cancer Institute researchers has revealed.

In the October issue of Nature Genetics, the investigators present the first complete map of the molecular "control panels" -- stretches of DNA that turn genes on and off -- operated by the cells' estrogen receptor, the master regulator of cell growth in the most common form of breast cancer. The map, which includes thousands of such control regions, provides scientists with a new tool for understanding how genes are regulated, and may eventually help doctors match patients with treatments that are most likely to be effective for them and overcome the problem of resistance to current hormone therapies, the study authors say.

The estrogen receptor (ER) is an intricate protein net in the nucleus of breast cancer cells. When the receptor snares an estrogen molecule, it sets in motion a cascade of activity among genes involved in cell growth and division. In many breast tumors, cells have an unusually large number of ERs, so they proliferate rapidly in the presence of estrogen. Drugs that block the ER, such as tamoxifen and fulvestrant, are often able to stop or slow the growth of these estrogen-driven tumors.

"For the most part, the sequence of steps between the activation of the estrogen receptor and the beginning of tumor cell division has been unclear. We've known of only a handful of the portions of genes that bind to the ER -- the so-called control regions that activate or deactivate the genes," says Dana-Farber's Myles Brown, MD, the senior author of the new study. "With this project we've located all of them, and found there are thousands more than were previously known." Since most genes have more than one control region, the map points to about 1,000 genes influenced, to some degree, by the E R.

The binding-site map was compiled with a novel two-step procedure called ChIP-on-chip. Researchers first used a technique called chromatin immunoprecipitation (ChIP) to purify the regions of genes that take orders from the ER. They then placed these pieces of DNA on "microarray chips" containing the entire human genome sequence. This allowed the researchers to identify all the points in the genome where binding with the ER takes place.

The researchers coined the word "cistrome" to describe the map they had produced -- an atlas of all gene segments influenced by the ER. "cis" refers to a DNA segment that regulates a gene's activity in response to a signal from outside the gene (while "trans" refers to a factor that acts on DNA); and "ome" -- from the Greek word for manager -- refers to the full set of such segments, as "genome" refers to all the genes within human cells.

The map contains many surprises, the study authors say. For one, the majority of binding sites within the cistrome are often very far from the portions of the genes that contain the blueprints for proteins. This overturns the commonly held notion that the ER might favor sites close to the protein-coding regions of genes.

"More than 70 percent of breast cancers are ER-positive, meaning their growth is driven by estrogen," Brown says, "and the estrogen receptor is the most important target for therapy for these tumors. Knowing the complete set of ER binding sites gives us a new resource for understanding the role of estrogen in breast cancer. By identifying genes associated with the ER in breast tumors, it opens up previously unexplored regions of the genome involved in the estrogen-dependence of breast cancer."

The knowledge may one day help researchers and physicians determine which treatments are likely to work best in individual patients and restore the potency of cancer drugs to which patients have become resistant, added Brown, who is also a profess or of medicine at Harvard Medical School.
'"/>

Source:Dana-Farber Cancer Institute


Related biology news :

1. Molecular biology fills gaps in knowledge of bat evolution
2. Molecular machine may lead to new drugs to combat human diseases
3. Molecular Motors Cooperate In Moving Cellular Cargo, Study Shows
4. Molecular models advance the fight against malaria
5. Molecular fossils uncover link between viruses and the immune system
6. Molecular thermometers on skin cells detect heat and camphor
7. Molecular messengers perform a crucial role in the ability of injured nerve cells to heal themselves
8. Molecular steps involved in the creation of gene-silencing microRNAs identified
9. Molecular miners find pain relief drugs from the sea
10. Molecular mechanism of feather formation found
11. Molecular trigger for Huntingtons disease found

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... CLEVELAND , June 27, 2016  Global ... average 4.6 percent through 2020 to $7.2 billion.  ... (food and beverages, cleaning products, biofuel production, animal ... and biotechnology, diagnostics, and biocatalysts). Food and beverages ... gains driven by increasing consumption of products containing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology: